Accelerating Drug Approval with Simoa®: Ultrasensitive Measurement of Biomarkers
Milena Dumont Milutinovic, Senior Manager of Field Applications at Quanterix, walks through the company’s ultrasensitive biomarker assay technology.
Quanterix fuels scientific discovery through ultrasensitive detection of protein biomarkers. To date, the company has delivered nearly 900 instruments to pharma and academic organisations across North America, Europe, and Asia. Its Simoa® technology has also been cited in over 2,000 peer-reviewed publications and counting.
A global company, Quanterix is headquartered outside of Boston, Mass., with support teams located across Europe. The guiding philosophy of its technology is simple: the higher the sensitivity, the greater the ability to detect proteins at their lowest levels, enabling scientists to detect disease earlier. Outlining the principles of Simoa technology and use cases, Milena Dumont Milutinovic, Senior Manager of Field Applications at Quanterix, presented at Oxford Global’s Biomarkers 2023 conference.